Sep 2026
Tofacitinib Reduces KL-6 Levels in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease. Results Of A Phase II Investigator-Initiated Study.
This trial estimates the rates of adverse events, mortality, low disease activity, PPF, decline in FVC in RA-ILD, and decline in serum KL-6 in patients treated with tofacitinib NCT05246293.
J. Rojas-Serrano, E. Ramos-Martínez, M. Mejía et al.
· Respiratory Medicine · 1 citation